Spinocerebellar ataxia type 7 (SCA7) is a neurodegenerative disorder caused by a CAG repeat expansion in the SCA7 gene leading to elongation of a polyglutamine tract in ataxin-7, a protein of unknown function. A putative ataxin-7 yeast orthologue (SGF73) has been identified recently as a new component of the SAGA (Spt/Ada/Gcn5 acetylase) multisubunit complex, a coactivator required for transcription of a subset of RNA polymerase II-dependent genes. We show here that ataxin-7 is an integral component of the mammalian SAGA-like complexes, the TATA-binding protein-free TAF-containing complex (TFTC) and the SPT3/TAF9/GCN5 acetyltransferase complex (STAGA). In agreement, immunoprecipitation of ataxin-7 retained a histone acetyltransferase activity, characteristic for TFTC-like complexes. We further identified a minimal domain in ataxin-7 that is required for interaction with TFTC/STAGA subunits and is conserved highly through evolution, allowing the identification of a SCA7 gene family. We showed that this domain contains a conserved Cys3His motif that binds zinc, forming a new zinc-binding domain. Finally, polyglutamine expansion in ataxin-7 did not affect its incorporation into TFTC/STAGA complexes purified from SCA7 patient cells. We demonstrate here that ataxin-7 is the human orthologue of the yeast SAGA SGF73 subunit and is a bona fide subunit of the human TFTC-like transcriptional complexes.
Spinocerebellar ataxia type 7 (SCA7) is a dominantly inherited neurodegenerative disorder, characterized by late-onset neuronal loss in cerebellum, brainstem and retina. SCA7 is caused by a CAG repeat expansion (38–460) in the SCA7 gene encoding ataxin-7, a 892 amino acids protein of unknown function (1,2). Initial sequence analysis only predicted a bipartite nuclear localization signal (NLS) shown to be functional in transfected cells (3). However, recent bioinformatic studies identified a significant block of homology between human ataxin-7 and a yeast open reading frame, YGL066w (4,5), which was identified recently as a novel subunit of the SAGA complex (Spt/Ada/Gcn5 acetylase) and named SGF73 (6,7).
The yeast SAGA complex is composed of Ada coactivators, Spt proteins, a subset of yeast TATA-binding protein (TBP)-associated factors (TAFs) and Tra1 (8,9). The yeast SAGA acts as a transcriptional coactivator/adapter required at specific promoters and possesses histone acetyltransferase (HAT) activity that is mediated by Gcn5. Human homologues of yeast Gcn5 include PCAF and GCN5 (10,11), which were found in several multiprotein complexes, such as TBP-free TAF complex (TFTC) (12), SPT3/TAF9/GCN5 acetyltransferase complex (STAGA) (13) and PCAF/GCN5 complexes (14). While still incompletely characterized, these multisubunit complexes show related, but not identical, compositions and presumably overlapping but also distinct functions. All contain TRRAP, the human homologue of yeast Tra1, homologues of yeast SAGA subunits and a subset of TAFs, but clearly lack the TBP (15). However, TFTC specifically contained TAF5 and TAF6, whose yeast homologues are also found in SAGA, whereas these subunits were not found in STAGA or in PCAF/GCN5 complexes (16). These complexes contain a GCN5 HAT activity and were shown to acetylate preferentially histone H3 in both free and nucleosomal contexts and to activate transcription on chromatin templates (12,17,18). Furthermore, TFTC was shown to direct preinitiation complex assembly in the absence of transcription factor IID (TFIID) on naked DNA templates (19). Recent findings also suggested a role for TFTC/STAGA complexes in DNA repair (17,20).
In this study, we demonstrated that ataxin-7 is an integral subunit of highly purified TFTC complex and that an anti-ataxin-7 antibody co-immunoprecipitated TFTC-like complexes and an HAT activity corresponding to that of GCN5. Furthermore, we identified a family of SCA7 genes conserved from human to yeast. Biochemical experiments showed that a highly conserved domain in ataxin-7 was able to bind zinc and was sufficient for interaction with TFTC/STAGA subunits. Finally, we showed that a polyglutamine (polyQ) expansion in ataxin-7 did not affect TFTC-like complex formation.
Ataxin-7 is a novel subunit of GCN5 HAT-containing complexes
A putative ataxin-7 yeast orthologue (SGF73, encoded by YGL066w) has been identified recently as a novel subunit of the SAGA complex (7). We thus asked whether human ataxin-7 is also a subunit of TFTC/STAGA complexes which are human homologues of the yeast SAGA complex. In order to test this hypothesis, we performed co-immunoprecipitation (IP) experiments using nuclear extract (NE) of HeLa cells. When an anti-ataxin-7 antibody was used to immunoprecipitate ataxin-7-associated proteins, we detected by western blot analysis ataxin-7 and the specific TFTC subunits TRRAP and GCN5 (Fig. 1A, lane 3), whereas these proteins were not detected in a control IP (Fig. 1A, lane 5). In addition, the anti-ataxin-7 antibody also immunoprecipitated TAF10, but not TBP. Conversely, an anti-TRRAP antibody immunopurified ataxin-7 together with other human TFTC subunits, as shown by western blotting (Fig. 1A, lane 4) and mass spectrometry (data not shown). These results suggest that ataxin-7 is associated with TRRAP in a large multiprotein complex. Importantly, an anti-TBP antibody failed to detect TBP in both ataxin-7- and TRRAP-immunopurified fractions (Fig. 1A, lanes 3 and 4), suggesting that human ataxin-7 is a component of TFTC, but not of TFIID, which specifically contains TBP. Comparison of the band intensities derived from equal quantities of crude NEs before (NE input, lane 2) or after (NE unbound, lane 1) TRRAP IP indicated that a significant amount of endogenous ataxin-7 is associated with TFTC-like complexes in vivo (lanes 3 and 4).
These results were further confirmed by using highly purified TFTC preparation (19). A monoclonal antibody against human ataxin-7 strongly and specifically detected a band at the expected size (110 kDa) in the highly purified TFTC complex (Fig. 1B). These results together unequivocally confirmed that ataxin-7 is a TFTC/STAGA subunit.
TFTC/STAGA complexes contain a HAT activity that is mediated by GCN5 (12). In order to confirm that endogenous ataxin-7 is an integral component of these complexes, we tested the ability of the ataxin-7 immunopurified complex to acetylate free histones using an in vitro assay. This assay was performed directly on sepharose beads after IP. As shown in Figure 1C, the ataxin-7 immunopurified fraction efficiently acetylated histone H3 and to a lesser extent histone H2B (lane 3). As a positive control, purified TFTC showed a similar pattern of histone acetylation (lane 1). In contrast no HAT activity was detected in control IP (lane 4). Altogether, these results demonstrated that human ataxin-7 is a novel subunit of GCN5 histone acetylase-containing complex TFTC/STAGA in vivo and thus likely the human orthologue of yeast SGF73 SAGA component.
Identification of conserved domains in ataxin-7
As ataxin-7 and SGF73 are part of an important evolutionarily conserved complex acting in eukaryotic transcriptional regulation, we next wanted to determine the pattern of ataxin-7 sequence conservation through evolution and searched for SCA7 homologue genes in various genomes. Four SCA7 paralogue genes were identified in the human genome and named SCA7, SCA7-L1, SCA7-L2 and SCA7-L3, encoding ATX7, ATX7-L1, ATX7-L2 and ATX7-L3, respectively (Fig. 2). These genes are unambiguous SCA7 paralogues as they were localized at distinct loci and found consistently in all vertebrate genomes analyzed (Homo sapiens, Mus musculus, Brachydanio rerio and Fugu rubripes). Sequence comparison of ATX7 family members revealed two conserved blocks: block I (residues 126–176 in human ATX7) and block II (residues 341–400). A third region (block III, residues 508–565) was conserved in all vertebrate sequences except in ATX7-L3 (Fig. 2A). The expandable polyQ motif is present and located N-terminal to block I in human ATX7 and in its vertebrate orthologues but is absent in ATX7 paralogues.
Using human ATX7 blocks I and II as query sequences, we retrieved several ATX7 homologues in more distant species: Ciona intestinalis (data not shown), Anopheles gambiae, Caenorhabditis briggsae (data not shown), Saccharomyces cerevisiae, Schizosaccharomyces pombe and Neurospora crassa. In these genomes, a single ATX7 sequence was found and characterized by a weakly conserved block I (16% identity between H. sapiens and S. cerevisiae) located N-terminal to a highly conserved block II (42% identity) and by absence of block III (Fig. 2A). This pattern and degree of conservation suggest that these yeast proteins are ATX7 orthologues. Interestingly, ATX7-L3 was also characterized by the absence of block III and showed a weaker homology to human ATX7 (34% identity for block II) than SGF73 (42% identity for block II). This suggested that SCA7-L3 might result from an ancient duplication of an ancestral SCA7 gene. Multiple alignments of the highly conserved block II identified several invariant residues across species allowing the definition of an ATX7 signature, as shown in Figure 2C. In particular, block II contained 3 Cys and 1 His (Cys3His, black triangles in Fig. 2C) forming a Cys-X9–10-Cys-X5-Cys-X2-His motif within a specific signature that was found only in ATX7 and its homologues.
Ataxin-7 is a zinc-binding protein
As ataxin-7 block II contained invariant residues with the potential to coordinate metal ions, we next asked whether human ataxin-7 binds a metal through this highly conserved domain. We constructed an expression vector that enabled the production of an ataxin-7 fragment (residues 311–406) encompassing block II fused to glutathione S-transferase (GST). After removal of the GST moiety (Fig. 3A), metal content of the purified recombinant ataxin-7 fragment was analyzed by electrospray ionization-mass spectrometry (ESI-MS). Measurements were performed in ammonium acetate for native conditions and in water–acetonitrile with formic acid for denaturing conditions. Under denaturing conditions, we detected one major ionization product of 12 848.7±0.3 Da, fitting with ataxin-7 fragment theoretical mass of 12 848.4 Da (data not shown). Under non-denaturing conditions, we detected one major product of 12 911.5±0.2 Da, revealing the presence of one zinc atom as deduced by comparing molecular masses obtained from denaturing and native conditions (Fig. 3B). No other ionization products of higher molecular weight were detected, indicating that this domain was monomeric in these conditions. Together, these results showed that this conserved block II corresponds to a folded zinc-binding domain (ZBD), confirming the functional relevance of the highly conserved Cys and His residues. This ataxin-7 domain (residues 311–406) is thereafter referred as ataxin-7 ZBD.
Human ataxin-7 ZBD interacts with TFTC/STAGA subunits
We next wanted to examine whether the highly conserved ZBD could directly recruit TFTC/STAGA complexes. We cloned and expressed the following fusion proteins: GST–ATX7 (311–406) which corresponds to the ZBD and GST–ATX7 (90–406) encompassing the block I and the ZBD (Fig. 4A). These recombinant proteins were produced and immobilized on glutathione–sepharose beads in parallel with GST alone as a control. We then tested the ability of these fusion proteins to interact with TFTC/STAGA subunits from HeLa NE. As shown by western blot analysis (Fig. 4B), all TFTC/STAGA subunits tested, TRRAP, GCN5 and TAF10, were recruited specifically from NEs by GST–ATX7 (311–406) and by GST–ATX7 (90–406), but not by the GST control. In contrast, ataxin-7 ZBD did not interact with TIF1β, which is a factor unrelated to these complexes. Interestingly, endogenous human ataxin-7, which is expressed at low levels in HeLa cells, was enriched significantly in the GST–ATX7-bound fraction when compared with the input NE. This result further suggests that the different GST–ATX7 fusion proteins pull-down entire TFTC-like complexes of which endogenous ataxin-7 is an integral component in HeLa cells.
To further delineate the domain interacting with TFTC subunits, we performed successive deletions of the GST–ATX7 (311–406) initial construct, removing the weakly conserved residues in the ZBD N- and C-terminal ends. Using five deletion constructs (Fig. 4A), we defined a minimal ZBD (330–401) that is sufficient to pull-down GCN5 and TAF10 (Fig. 4C).
PolyQ expansion in ataxin-7 does not affect TFTC-like complexes formation
The SCA7 mutation is an expansion of a polyQ tract in ataxin-7 N-terminal part (Fig. 4A) which confers a gain of function to the mutant protein. SCA7 belongs to a group of neurodegenerative disorders, including Huntington's disease, caused by a polyQ expansion. A hallmark of these disorders is the aggregation of polyQ proteins into insoluble nuclear inclusions (NIs).
First, we wanted to determine whether the polyQ expansion would affect the association of ataxin-7 with TFTC/STAGA complexes. We performed co-IP experiments using whole cell extracts (WCEs) of HEK293 cells transfected with constructs expressing FLAG-tagged full-length ataxin-7 carrying either 10 or 60 glutamines. Anti-FLAG immunoprecipitated fractions were analyzed by western blot analysis. Interestingly, normal and mutant ataxin-7 equally interacted with the TFTC subunits TRRAP, GCN5 and TAF10 (Fig. 5A). These proteins were not detected after anti-FLAG IP performed on mock transfected HEK293 cells (Fig. 5A). Normal and mutant recombinant ataxin-7 were immunoprecipitated specifically and efficiently using anti-FLAG antibody. In order to confirm this result in vivo, we performed co-IP experiments using lymphoblastoid cell lines, derived from an SCA7 patient, expressing both normal (10 Q) and mutant (51 Q) ataxin-7 (Fig. 5B, lane 1). Both normal and mutant ataxin-7 were immunoprecipitated specifically from NEs of SCA7 cells with an anti-TRRAP (Fig. 5B, lane 2) or with an anti-ataxin-7 antibody (Fig. 5B, lane 3). The bands corresponding to normal and expanded ataxin-7 were of comparable intensities in both TRRAP and ataxin-7 IPs, indicating that both forms of ataxin-7 are equally incorporated within TFTC/STAGA complexes in SCA7 cells. Two percent of the amount of NE used for IP was loaded on the gel (Fig. 5B, lane 1) and revealed that endogenous ataxin-7 was enriched significantly after TRRAP IP (Fig. 5B, lane 2). Furthermore, we performed an anti-TRRAP IP using NEs from SCA7 cells used in Figure 5B or from control lymphoblastoid cells derived from an unaffected individual, only expressing normal ataxin-7. Western blot analysis of TRRAP-associated proteins showed that GCN5 and TAF10 were similarly immunopurified from both cell lines (Fig 5C, lanes 2 and 3). Ten percent of the amount of NE used for IP was loaded on the gel (Fig. 5C, lane 1) and revealed that endogenous TRRAP was enriched efficiently after IP (Fig. 5C, lane 2), in both the control and the SCA7 cell line. These results together indicate that TFTC/STAGA subunit composition is not altered by polyQ expansion in ataxin-7.
We then investigated whether expanded ataxin-7 would recruit and sequester TFTC/STAGA subunits into NIs. We transfected truncated SCA7 cDNA constructs with 10 or 60 CAG encompassing the block I, the ZBD and the NLS. Immunostaining revealed that normal and mutant recombinant ataxin-7 were localized exclusively in the nucleus from HeLa (Fig. 5B), COS-1, NIH-3T3 and HEK293 cells (data not shown), confirming that the predicted bipartite NLS is functional in these cells. This result is surprisingly contradictory with a recent study suggesting that this NLS was not functional by using a comparable ataxin-7 construct (residues 1–460) in transfection experiments using HEK293 cells (21). Mutant ataxin-7 (residues 1–456) either displayed a diffuse nuclear staining or accumulated into large NIs (Fig. 5B). Endogenous TAF10 showed an identical homogenous nuclear localization in HeLa cells transfected with either normal or mutant SCA7 constructs. In particular, TAF10 was not recruited in NIs and not depleted from its normal localization (Fig. 5B). Similar results were obtained for TRRAP (data not shown). Altogether, these results show that ataxin-7 incorporation into TFTC/STAGA complexes is not altered by a polyQ expansion and that nuclear distribution of TFTC/STAGA subunits (TAF10, TRRAP) is not affected by mutant ataxin-7 aggregation in transfected cells.
Identification and multiple alignments of ATX7 homologues revealed significant conservation of three blocks. Block II is conserved highly through evolution, from human to yeast, and allowed us to define an ATX7 signature (Fig. 2C). Notably, we noticed strictly conserved Cys and His forming a Cys-X9–10-Cys-X5-Cys-X2-His motif that exhibits similarities with the Nup475 family consensus sequence (Cys-X8-Cys-X5-Cys-X3-His). This domain has been shown previously to coordinate zinc through the conserved Cys and His residues and to fold into a new structural zinc-finger motif (22,23). Nup475 structure revealed a mainly extended region stabilized by zinc coordination and two hydrophobic cores. Secondary structure prediction of ataxin-7 block II revealed a nearly complete lack of regular secondary structural elements (data not shown). Despite the presence of a zinc coordination unit, as demonstrated by mass spectrometry (Fig. 3), absence of any stabilizing hydrophobic interactions in ataxin-7 block II suggested that it forms a novel zinc-binding fold. Furthermore, the ataxin-7 block II consensus sequence is markedly different from that of the Nup475 family, except the Cys3His motif. Resolution of ataxin-7 block II three-dimensional structure should elucidate the folding of this atypical zinc-finger motif. Further experiments are also required to determine which residues bind zinc and whether zinc-binding is necessary for ataxin-7 incorporation into TFTC/STAGA complexes. The highly conserved residues in ataxin-7 block II between yeast SGF73 and mammalian ATX7s and the lack of high homology in their other domains suggest that these residues are involved in ataxin-7 architecture and/or interaction with other TFTC/STAGA subunits.
Block I is less conserved (16% identity between human and yeast) but is characterized by a high conservation of Cys and His forming a Cys-X2-Cys-X11-His-X3–4-His/Cys motif (Fig. 2B), which is reminiscent of C2H2 zing-finger motifs although with a different spacing (24). Block III is found only in vertebrates ATX7, ATX7-L1 and ATX7-L2 and is characterized by the presence of several aromatic, charged and polar residues. However, it did not match any previously described motif (Fig. 2D). Function of blocks I and III remains to be elucidated, in particular whether these domains are also involved in interaction with specific TFTC/STAGA subunits. In agreement, several subunits have been shown to interact with distinct partners within these complexes (25).
Immunoprecipitation of endogenous ataxin-7 from HeLa cells specifically retrieved TFTC/STAGA subunits together with a GCN5 characteristic HAT activity. Accordingly, ataxin-7 did not interact with TBP which is specific for the TFIID transcriptional complex. Altogether, these results demonstrate that ataxin-7 is a novel subunit of TFTC-like complexes and is the orthologue of the yeast SAGA-associated factor SGF73 (Table 1). We have shown that ataxin-7 ZBD (block II, residues 330–401) is sufficient to pull-down these complexes. It remains to be determined which subunit(s) directly interacts with this domain and whether ataxin-7 is required for TFTC/STAGA integrity and activity. Many TAFs paralogues can participate in TFTC formation and have redundant and complementary roles in transcriptional regulation (26). It would thus be interesting to analyze ATX7 paralogues expression profiles, whether these different proteins can be present in TFTC-like complexes and their respective roles in vivo. Particularly, ATX7 family members harbouring block III might have a specific function as this domain is not present in SGF73 and thus not required for SAGA complex assembly.
Ataxin-7 is the fourth member of the polyQ disease genes, besides the androgen receptor, the TBP and the atrophin-1 (36), whose normal function is involved in transcriptional regulation. Interestingly, recent findings indicate that transcriptional dysregulation contribute to the pathogenesis of polyQ-induced neuronal dysfunction (27,28) and might be mediated by defects in histone acetylation. This hypothesis is based on the observations that CREB-binding protein HAT activity is impaired by expanded polyQ in vitro and that histone deacetylase inhibitors are protective in Huntington's disease mouse and Drosophila models (29–31). Severe downregulation of genes encoding components of the phototransduction pathway has been reported consistently in photoreceptors from three different SCA7 mouse models (32–34). Thus, it is tempting to speculate that polyQ expansion in ataxin-7 would impair TFTC/STAGA HAT activity, thereby contributing to the transcriptional alterations observed in SCA7. Notably, expanded ataxin-7 aggregation might decrease the amount of TFTC/STAGA complexes containing ataxin-7 and/or sequester TFTC/STAGA subunits from their normal localization in neurons from SCA7 mouse models. However, two recent experimental evidences suggested that a partial loss of ataxin-7 function is unlikely to occur in SCA7 pathogenesis. First, Yoo et al. (33) recently demonstrated that SCA7 toxicity results from a gain of function mechanism using mice in which a 266 CAG repeat was targeted into the mouse Sca7 locus. Compound heterozygous mice carrying an expanded Sca7 allele and a Sca7 null allele are not affected more severely than heterozygous mice carrying an expanded Sca7 allele and a wild-type Sca7 allele (33). Second, overexpression of normal ataxin-7 did not modulate phenotype severity in another SCA7 transgenic mouse model (34).
We demonstrated that both normal and mutant ataxin-7 can be incorporated in TFTC/STAGA complexes immunopurified from SCA7 patient cell lines and that the incorporation of mutant ataxin-7 did not alter the composition of TFTC/STAGA complexes. It will thus be of major interest to assess HAT activity from TFTC/STAGA complexes containing either normal or mutant ataxin-7. A decreased HAT activity of mutant ataxin-7 containing complexes is unlikely to occur as a partial loss of ataxin-7 function does not appear to contribute to SCA7 pathogenesis. Thus, a polyQ expansion in these complexes could lead either to an increased HAT activity or to a non-regulated transcriptional activity of the TFTC/STAGA complexes. Finally, SCA7 mice revealed selective stabilization of expanded ataxin-7 versus normal ataxin-7 (33,35). It would then be worth testing whether the reduced turnover of expanded ataxin-7 would increase the proportion of TFTC complexes containing mutant ataxin-7 and thereby contribute to SCA7 pathogenesis.
MATERIALS AND METHODS
We have used the two core domains (blocks I and II) of human ataxin-7 (ATX7) as query sequences in BLAST (37) searches in the SwissProt/TrEMBL protein sequences databases and in various genomes. We introduced the following nomenclature for human ATX7 paralogues: ATX7-L1 for KIAA1218, ATX7-L2 for FLJ00381 and ATX7-L3 for FLJ31440. Sequences were then aligned using ClustalX (38) and the figure was generated with Alscript 2.04 (39). Secondary structure of ataxin-7 block II was calculated using the PHD program (40).
Plasmids construction and GST pull-down assays
For cell transfection experiments, full-length SCA7 cDNAs with either 10 or 60 CAGs were obtained by PCR amplification of, respectively, pαaIA and pαbIA constructs (41), using a 5′ primer encoding a FLAG epitope. These fragments were subcloned into pcDNA3.1(+) (Invitrogen) to generate pc7NFL and pc7EFL. Truncated SCA7 constructs (pc7N456 and pc7E456) were generated by PCR amplification of pc7NFL and pc7EFL and re-introduced into pcDNA3.1(+) vector (Invitrogen). Blocks I and II SCA7 constructs [ATX7 (311–406), (90–406), (323–401), (330–401), (337–401), (330–389) and (330–377)] were generated by PCR amplification of pc7NFL and introduced into the pGEX-4T-1 plasmid (Amersham Pharmacia Biotech). These constructs were expressed in Escherichia coli BL21 (DE3) strain and purified according to manufacturer's instructions. Fusion proteins bound to glutathione–sepharose beads were incubated with NEs of HeLa cells in lysis buffer (50 mM Tris–HCl pH 7.9, 10% glycerol, 1 mM EDTA, 150 mM NaCl, 5 mM MgCl2, 0.1% NP-40 and protease inhibitors). After extensive washing, bound proteins were analyzed by western blot.
Mass spectrometry measurements
Affinity purified GST–ATX7 (311–406) was recovered by elution with glutathione (GSH) and further purified by fast performance liquid chromatography on a Pharmacia Superdex S200(16/90) gel-filtration column in a buffer with 10 mM Tris–HCl pH 7.5 and 150 mM NaCl. One unit of bovine thrombin (Sigma T-6634) was added for 72 h in order to cleave the GST, which was removed finally by affinity on GSH–sepharose beads. The flow-through containing ATX7 (311–406) was then dialysed against 200 mM ammonium acetate (pH 7.0), concentrated with Centricon 3 kDa (Millipore) and submitted to electrospray ionization-time of flight mass spectrometry (LCT, Waters, UK). Samples were diluted to 10 pmol/µl in 50 mM ammonium acetate buffer and infused continuously into the ESI ion source at a flow rate of 6 µl/min through a Harvard syringe pump. Parameters were optimized so that non-covalent interactions survive the ionization/desorption process. The accelerating voltage, which controls the kinetic energy communicated to the ions in the interface region of the mass spectrometer, was set to 120 V, and the pressure to 5 mbar. The ESI-MS data were acquired in the positive ion mode in the mass range 500–4000 m/z. Calibration of the instrument was performed by using the multiply charged ions produced by a separate injection of horse heart myoglobine diluted to 2 pmol/µl in a 1 : 1 water–acetonitrile mixture (v/v) acidified with 1% of formic acid.
Western blot, IPs and HAT assays
The anti-TRRAP polyclonal (1930) and monoclonal (2TRR-2D5) antibodies were generated by immunization of rabbits and mice with peptides corresponding to aminoacids 198–219 (VKVNPEREDSETRTHSIIPRGS) and 2005–2024 (DQQPDSDMDPNSSGEGVNSV) of human TRRAP, respectively, as described (20). Western blot analyses were performed as described using anti-ataxin-7 (41), anti-TIF1β (42), anti-GCN5 (20), anti-TAF10 and anti-TBP (19) monoclonal antibodies. IPs were carried out using anti-ataxin-7 [1261, (41)] and anti-TRRAP (1930) polyclonal antibodies as described (20). Protein complexes bound to protein A–sepharose beads were either boiled and processed for western blot analysis or used for HAT assays, as described (12). TFTC complex was purified as described previously (19).
Cell transfection and immunocytofluorescence
Two×105 HeLa or HEK293 cells were transfected by calcium phosphate precipitation. For immunocytofluorescence, cells were fixed in 4% paraformaldehyde and immunostaining was carried out using anti-ataxin-7 [1261 (41)] and anti-TAF10 [6TA-2B11 (19)] antibodies, as described (20).
We thank Y. Trottier and K. Merienne for discussions. We are grateful to M. Oulad-Abdelghani and G. Duval for generating the monoclonal and polyclonal TRRAP antibodies, to R. Losson for gift of anti-TIF1β antibody and to G. Stevanin for SCA7 lymphoblastoid cell lines. This study was supported by grants from Institut National de la Santé et de la Recherche Médicale, the Centre National de la Recherche Scientifique and the Hôpital Universitaire de Strasbourg (HUS) to D.D. and L.T., the Hereditary Disease Foundation and from the European Community (EUROSCA integrated project, LSHM-CT-2004-503304) to D.D. and by Association pour la Recherche sur le Cancer, the Fondation pour la Recherche Médicale, the Fonds National de la Science (FNS) ACI, European Community (HPRN-CT-2000-00087 and HPRN-CT-2000-00088), INTAS and AICR (03-084) grants to L.T. D.H. was supported by a fellowship from the Fondation pour la Recherche Médicale, S.H. by a fellowship from the Ministère de la Recherche et de la Technologie and F.R. by a fellowship from the CNRS and Région Alsace.
|TBP-free HAT complexes|
|SAGA (yeast)||TFTC/STAGA/PCAF (human)|
|TBP-free HAT complexes|
|SAGA (yeast)||TFTC/STAGA/PCAF (human)|
Sgf, SAGA-associated factor; Ubp, ubiquitin protease; SAP, spliceosome-associated protein; ND: non-defined.